348 related articles for article (PubMed ID: 37057106)
21. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.
Pan Y; Deng C; Qiu Z; Cao C; Wu F
Front Oncol; 2021; 11():713530. PubMed ID: 34660278
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
23. Treating ALK-positive non-small cell lung cancer.
Ziogas DC; Tsiara A; Tsironis G; Lykka M; Liontos M; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):141. PubMed ID: 29862230
[TBL] [Abstract][Full Text] [Related]
24. Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions.
Schenk EL
Transl Lung Cancer Res; 2023 Feb; 12(2):322-336. PubMed ID: 36895933
[TBL] [Abstract][Full Text] [Related]
25. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
Somasundaram A; Socinski MA; Burns TF
Expert Opin Pharmacother; 2014 Dec; 15(18):2693-708. PubMed ID: 25381900
[TBL] [Abstract][Full Text] [Related]
26. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
27. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
28. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
29. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
30. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application.
Maione P; Sacco PC; Sgambato A; Casaluce F; Rossi A; Gridelli C
Ther Adv Med Oncol; 2015 Sep; 7(5):263-73. PubMed ID: 26327924
[TBL] [Abstract][Full Text] [Related]
31. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
Passaro A; Lazzari C; Karachaliou N; Spitaleri G; Pochesci A; Catania C; Rosell R; de Marinis F
Onco Targets Ther; 2016; 9():6361-6376. PubMed ID: 27799783
[TBL] [Abstract][Full Text] [Related]
32. Optimal management of ALK-positive NSCLC progressing on crizotinib.
Metro G; Tazza M; Matocci R; Chiari R; Crinò L
Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
[TBL] [Abstract][Full Text] [Related]
33. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
34. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Cooper AJ; Sequist LV; Lin JJ
Nat Rev Clin Oncol; 2022 Aug; 19(8):499-514. PubMed ID: 35534623
[TBL] [Abstract][Full Text] [Related]
35. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
36. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
37. Anti-Angiogenic Therapy in
Tan AC; Pavlakis N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012123
[TBL] [Abstract][Full Text] [Related]
38. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
[TBL] [Abstract][Full Text] [Related]
39. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
40. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]